---
figid: PMC6461577__gr8
figtitle: Fludarabine Improves NDV-Mediated Oncolytic Viro-immunotherapyOn the one
  hand, the viral RNA activates the cytoplasmic RIG-I signaling pathway in the host
  cells to produce type I IFNs or other antiviral molecules
organisms:
- Hepatitis B virus
- Human alphaherpesvirus 1
- Measles morbillivirus
- Human alphaherpesvirus 3
- Reovirus sp.
- Ebola virus sp.
- Replication competent viruses
- Homo sapiens
- Mus musculus
- Bos taurus
- Gallus gallus
- Armoracia rusticana
- NA
- NA
- NA
- NA
- NA
organisms_ner:
- Bos taurus
- Mus musculus
- Homo sapiens
- Gallus gallus
- Danio rerio
pmcid: PMC6461577
filename: gr8.jpg
figlink: /pmc/articles/PMC6461577/figure/fig8/
number: F8
caption: 'Fludarabine Improves NDV-Mediated Oncolytic Viro-immunotherapyOn the one
  hand, the viral RNA activates the cytoplasmic RIG-I signaling pathway in the host
  cells to produce type I IFNs or other antiviral molecules. Autocrine or paracrine
  of IFNs activate STAT1 signaling pathway to amplify the antiviral loop. Fludarabine
  blocks this feedforward loop and favors viral replication at an early stage after
  infection. Increased viral replication in the host cells results in more IFN production
  at the late stage of infection, which further activates antitumor immune responses
  (left). On the other hand, fludarabine increases proteasomal degradation of p-STAT3
  and IDO1 by accelerating ubiquitination of target proteins, in turn, blocks immune
  suppression (right). Abbreviations: RIG-I, retinoic acid-inducible gene I; MAVS,
  mitochondrial antiviral-signaling protein; IRF3/7, interferon regulatory factor
  3/7; IFNAR, interferon-α/β receptor; JAK, Janus kinase; IL-6R, interleukin-6 receptor;
  Ub, ubiquitin; Trp, tryptophan; Kyn, kynurenine.'
papertitle: Fludarabine as an Adjuvant Improves Newcastle Disease Virus-Mediated Antitumor
  Immunity in Hepatocellular Carcinoma.
reftext: Gang Meng, et al. Mol Ther Oncolytics. 2019 Jun 28;13:22-34.
year: '2019'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.936089
figid_alias: PMC6461577__F8
figtype: Figure
redirect_from: /figures/PMC6461577__F8
ndex: 67eaaf0a-df07-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC6461577__gr8.html
  '@type': Dataset
  description: 'Fludarabine Improves NDV-Mediated Oncolytic Viro-immunotherapyOn the
    one hand, the viral RNA activates the cytoplasmic RIG-I signaling pathway in the
    host cells to produce type I IFNs or other antiviral molecules. Autocrine or paracrine
    of IFNs activate STAT1 signaling pathway to amplify the antiviral loop. Fludarabine
    blocks this feedforward loop and favors viral replication at an early stage after
    infection. Increased viral replication in the host cells results in more IFN production
    at the late stage of infection, which further activates antitumor immune responses
    (left). On the other hand, fludarabine increases proteasomal degradation of p-STAT3
    and IDO1 by accelerating ubiquitination of target proteins, in turn, blocks immune
    suppression (right). Abbreviations: RIG-I, retinoic acid-inducible gene I; MAVS,
    mitochondrial antiviral-signaling protein; IRF3/7, interferon regulatory factor
    3/7; IFNAR, interferon-α/β receptor; JAK, Janus kinase; IL-6R, interleukin-6 receptor;
    Ub, ubiquitin; Trp, tryptophan; Kyn, kynurenine.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - IL6
  - IDO1
  - RIGI
  - MAVS
  - STAT3
  - IRF3
  - IRF7
  - STAT1
  - IFNAR1
  - Il6
  - Ido1
  - Rigi
  - Mavs
  - Stat3
  - Irf3
  - Irf7
  - Stat1
  - oh
  - H2-Aa
  - Ifnar1
  - Ppp1r3f
  - Rfpw3
  - JAK1
  - JAK2
  - JAK3
  - TYK2
  - il6
  - ido1
  - rigi
  - mavs
  - stat3
  - irf3
  - irf7
  - stat1a
  - stat1b
  - stat4
  - Trp
  - EFludarabine
  - Amino acids
---
